HB 2176 — Drug therapy agreements/PRA

Summary

Exempting information in collaborative drug therapy agreements from disclosure under the public records act.

Bill Text

Compared against the Revised Code of Washington as published AI-generated reading aid — verify against the official bill.

This bill amends 1 section(s) of the Revised Code of Washington: RCW 42.56.360.

• RCW 42.56.360

  (m) Data submitted to the data integration platform under RCW 71.24.908. (2) Chapter 70.02 RCW applies to public inspection and copying of health care information of patients. (3)(a) Documents related to infant mortality reviews conducted pursuant to RCW 70.05.170 are exempt from disclosure as provided for in RCW 70.05.170(3). (b)(i) If an agency provides copies of public records to another agency that are exempt from public disclosure under this subsection (3), those records remain exempt to the same extent the records were exempt in the possession of the originating entity. (ii) For notice purposes only, agencies providing exempt records under this subsection (3) to other agencies may mark any exempt records as "exempt" so that the receiving agency is aware of the exemption, however whether or not a record is marked exempt does not affect whether the record is actually exempt from disclosure. (4) Information and documents related to maternal mortality reviews conducted pursuant to RCW 70.54.450 are confidential and exempt from public inspection and copying. (5) Patient health care information contained in reports submitted under RCW 71.24.847(2) are confidential and exempt from public inspection. (6)(a) Collaborative drug therapy agreements, the contents of which are determined by the pharmacy quality assurance commission by rule pursuant to their rule-making authority under RCW 18.64.005, and any attachments or appendices to the collaborative drug therapy agreement, are confidential and may not be disclosed under this chapter except as provided for under (b) of this subsection (6). (b) A collaborative drug therapy agreement may be disclosed if that collaborative drug therapy agreement is the basis of an order or stipulation finding misconduct and resulting in a disciplinary action against a license holder regulated by a disciplining authority identified in RCW 18.130.040, including all license holders regulated by the pharmacy quality assurance commission. If a collaborative drug therapy agreement is disclosed pursuant to this subsection, personally identifiable information contained in such collaborative drug therapy agreement, other than that of a disciplined license holder, is confidential and may not be disclosed under this chapter. (c) For the purposes of this subsection (6), "personally identifiable information" means names, mailing addresses, credential numbers, email addresses, practice site facility addresses, and practice site facility phone numbers. --- END ---

  amended

Action History

1. February 19, 2026

   House Rules "X" file.

Sponsors

• (Thai) · Primary

Subjects